(SCLX) Scilex Holding - Ratings and Ratios

Scilex Holding Company (NASDAQ:SCLX) is a specialized pharmaceutical company focused on developing, acquiring, and commercializing non-opioid pain management therapies. Its product portfolio addresses both acute and chronic pain conditions, targeting conditions such as neuropathic pain, migraines, and gout. The company’s commercialized products include ZTlido, a prescription lidocaine topical solution for postherpetic neuralgia (PHN); ELYXYB, an oral solution for acute migraine treatment; and GLOPERBA, a liquid oral colchicine formulation for gout prophylaxis.

The company’s pipeline includes three developmental candidates: SP-102, a viscous gel formulation of dexamethasone for sciatica treatment, which has completed Phase 3 trials; SP-103, a higher-concentration lidocaine formulation for chronic neck and low back pain, currently in Phase 2; and SP-104, a low-dose naltrexone formulation for fibromyalgia, which has completed Phase 1 trials. Scilex collaborates with ACEA Therapeutics to expand its ZTlido program. Headquartered in Palo Alto, California, the company operates in the pharmaceutical sector with a focus on pain management solutions.

Ticker Symbol: SCLX, Exchange: NASDAQ, Type: common stock, Country Origin: United States, GICS Sub Industry: Pharmaceuticals

3-Month Forecast: Based on and , the stock is expected to face resistance at SMA50 (0.39) and SMA200 (0.95) levels, with potential short-term weakness due to the gap between the last price (0.31) and SMA20 (0.32). The low ATR (0.04) suggests limited volatility, but the stock may struggle to break above key resistance levels. indicates a high P/B ratio (28.85) and positive RoE (33.47), suggesting potential long-term value but near-term challenges due to valuation concerns.